TGFB1 and melanoma: Several compounds that block TGF-β signaling have shown encouraging results in the mouse PDAC models, and GC1008 (Fresolimumab) is an antibody against TGF-β, which has successfully completed phase I trial in renal cell carcinoma and advanced melanoma patients (NCT00356460) [33].